Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 6/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13345308 | 0.95 | CXCR2 (0.37) | CXCR2CXCR1KMT2AKDM4EMEN1 | |
| SCHEMBL14621814 | 0.92 | CXCR2 (0.37) | CXCR2CXCR1KMT2AKDM4EMEN1 | |
| SCHEMBL13345166 | 0.86 | CXCR2 (0.46) | CXCR2CXCR1KMT2AALDH1A1MAPT | |
| SCHEMBL13345139 | 0.86 | CXCR1 (0.39) | CXCR2CXCR1 | |
| SCHEMBL13344913 | 0.86 | CXCR2 (0.38) | CXCR2CXCR1KMT2AKDM4EMEN1 | |
| SCHEMBL13345105 | 0.85 | CXCR2 (0.48) | CXCR2CXCR1 | |
| SCHEMBL13208972 | 0.83 | CXCR2 (0.48) | CXCR2CXCR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL14639807 | 0.83 | CXCR2 (0.36) | CXCR2CXCR1KMT2AKDM4EMEN1 | |
| SCHEMBL13208095 | 0.83 | CXCR2 (0.37) | CXCR2CXCR1KMT2AKDM4EMEN1 | |
| SCHEMBL13345167 | 0.82 | CXCR2 (0.43) | CXCR2CXCR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718678-B2 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | CXCR3, CXCR1, CXCR2 | CXCR2 3/4885CXCR1 2/4885KMT2A 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.